Andrew P Beelen (Andrew Beelen)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Neoadjuvant Chemotherapy

Top Venues

Clinical drug investigation

Future oncology (London, England)

Cancer research

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Ramsha Iqbal, Maqsood M Yaqub, Husseyin O Bektas, Daniela-Elena Oprea-Lager, Elisabeth G E de Vries, Andor W J M Glaudemans, Philippe Aftimos, Géraldine Gebhart, Andrew P Beelen, Robert C Schuit, Albert D Windhorst, Ronald Boellaard, Catharina Willemien Menke-van der Houven van Oordt
[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Craig M Goodwin, Andrew M Waters, Jennifer E Klomp, Sehrish Javaid, Kirsten L Bryant, Clint A Stalnecker, Kristina Drizyte-Miller, Bjoern Papke, Runying Yang, Amber M Amparo, Irem Ozkan-Dagliyan, Elisa Baldelli, Valerie Calvert, Mariaelena Pierobon, Jessica A Sorrentino, Andrew P Beelen, Natalie Bublitz, Mareen Lüthen, Kris C Wood, Emanuel F Petricoin, Christine Sers, Autumn J McRee, Adrienne D Cox, Channing J Der
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. Cancer research (2022)
Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andrić, Andrew P Beelen, Jingshan Zhang, John S Yi, Rajesh K Malik, Joyce O'Shaughnessy
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future oncology (London, England) (2022)
Chao Li, Janet K Horton, Mark Sale, Laura Curd, Vineet Goti, Wenli Tao, Andrew P Beelen
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Clinical drug investigation 42 (8) (2022)